The Case for Prostate Cancer Screening with Prostate-Specific Antigen

European Urology, Supplements

Volumn 5, Issue 12, 2006, Pages 737-745

  Andriole, Gerald ^a   Djavan, Bob ^b   Fleshner, Neil ^c   Schröder, Fritz ^d  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Detection; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; LYCOPENE; PROSTATE SPECIFIC ANTIGEN; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER MORTALITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; INTERVENTION STUDY; LABORATORY DIAGNOSIS; MAXIMUM ALLOWABLE CONCENTRATION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SCREENING; STATISTICAL ANALYSIS; TIME;

EID: 33746708680     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.06.013     Document Type: Review

References (65)

1. Ablin R.J., Soanes W.A., Bronson P., and Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertil 22 (1970) 573-574
2. Guinan P., Bhatti R., and Ray P. An evaluation of prostate specific antigen in prostatic cancer. J Urol 137 (1987) 686-689
3. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
4. Thompson I.M., Bermejo C., Hernandez J., Basler J.A., and Canby-Hagino E. Screening for prostate cancer: opportunities and challenges. Surg Oncol Clin N Am 14 (2005) 747-760
5. Loeb S., Roehl K.A., Antenor J.A., et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67 (2006) 316-320
6. Whittemore A.S., Cirillo P.M., Feldman D., and Cohn B.A. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans. J Urol 174 (2005) 872-876 discussion 876
7. Andriole G.L. Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty. J Urol 174 (2005) 413-414
8. Gray J.M. Population screening and patient testing using PSA. BJU Int 95 Suppl 3 (2005) i
9. United Kingdom National Screening Committee. Second report of the national screening committee. 2004. Available at www.nsc.nhs.uk.
10. Cancer Facts and Figures 2005. Atlanta, GA: American Cancer Society, 2005.
11. Sarma A.V., and Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol 20 (2002) 3-9
12. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
13. Etminan M., FitzGerald J.M., Gleave M., and Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control 16 (2005) 1125-1131
14. Mills P.K., Beeson W.L., Phillips R.L., and Fraser G.E. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64 (1989) 598-604
15. Mohanty N.K., Saxena S., Singh U.P., Goyal N.K., and Arora R.P. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol 23 (2005) 383-385
16. Chan J.M., Gann P.H., and Giovannucci E.L. Role of diet in prostate cancer development and progression. J Clin Oncol 23 (2005) 8152-8160
17. Smith JA. A prospective study of physical activity and incident and fatal prostate cancer: Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC, Department of Nutrition, Harvard School of Public Health, Boston, MA. Urol Oncol 2005;23:463-4.
18. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
19. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
20. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
21. Roobol M.J., Schroder F.H., and Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 66 (2006) 604-612
22. Freedland S.J., Mangold L.A., Walsh P.C., and Partin A.W. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 174 (2005) 1276-1281 discussion 1281; author reply 1281
23. Catalona WJ, Yu X, Roehl KA, et al. Serum PSA correlates more strongly with percentage of cancer and cancer volume than with prostate size. Abstract presented at the American Urological Association Annual Meeting, San Antonio, TX, 21-26 May 2005.
24. Catalona W.J., and Loeb S. The PSA era is not over for prostate cancer. Eur Urol 48 (2005) 541-545
25. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
26. Aleman M., Karakiewicz P.I., Kupelian P., et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology 62 (2003) 70-74
27. Datta M.W., Dhir R., Dobbin K., et al. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource. J Urol 173 (2005) 1546-1551
28. Carter H.B. Prostate cancers in men with low PSA levels-must we find them?. N Engl J Med 350 (2004) 2292-2294
29. Schroder F.H., and Kranse R. Verification bias and the prostate-specific antigen test-is there a case for a lower threshold for biopsy?. N Engl J Med 349 (2003) 393-395
30. Carroll P.R. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both?. J Urol 173 (2005) 1061-1062
31. Welch H.G., Schwartz L.M., and Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 97 (2005) 1132-1137
32. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
33. Schroder F.H., Raaijmakers R., Postma R., van der Kwast T.H., and Roobol M.J. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 174 (2005) 489-494 discussion 493-4
34. van der Cruijsen-Koeter I.W., van der Kwast T.H., and Schroder F.H. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 95 (2003) 1462-1466
35. Hugosson J., Aus G., Lilja H., et al. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 169 (2003) 1720-1723
36. Postma R., Roobol M., Schroder F.H., and van der Kwast T.H. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 100 (2004) 968-975
37. Roobol M.J., Roobol D.W., and Schroder F.H. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65 (2005) 343-346
38. Kundu S.D., Grubb R.L., Roehl K.A., et al. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol 173 (2005) 1116-1120
39. Djavan B., Fong Y.K., Ravery V., et al. Are repeat biopsies required in men with PSA levels ≤4 ng/ml? A multiinstitutional prospective European study. Eur Urol 47 (2005) 38-44 discussion 44
40. Remzi M., Fong Y.K., Dobrovits M., et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 174 (2005) 1256-1260 discussion 60-1; author reply 61
41. Daneshgari F., Taylor G.D., Miller G.J., and Crawford E.D. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 45 (1995) 604-609
42. Chen M.E., Troncoso P., Johnston D.A., Tang K., and Babaian R.J. Optimization of prostate biopsy strategy using computer based analysis. J Urol 158 (1997) 2168-2175
43. Vashi A.R., Wojno K.J., Gillespie B., and Oesterling J.E. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 159 (1998) 920-924
44. Steiner H., Moser P., Hager M., et al. Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. Prostate 58 (2004) 277-282
45. Hernandez J., and Thompson I.M. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101 (2004) 894-904
46. Shah J.B., Reese A.C., McKiernan J.M., and Benson M.C. PSA updated: still relevant in the new millennium?. Eur Urol 47 (2005) 427-432
47. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417-424
48. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 (1999) 83-91
49. Friedman G.D., Hiatt R.A., Quesenberry Jr. C.P., and Selby J.V. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 337 (1991) 1526-1529
50. Richert-Boe K.E., Humphrey L.L., Glass A.G., and Weiss N.S. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 5 (1998) 99-103
51. Derweesh I.H., Kupelian P.A., Zippe C., et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 22 (2004) 300-306
52. Kopec J.A., Goel V., Bunting P.S., et al. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 174 (2005) 495-499 discussion 499
53. van der Cruijsen-Koeter I.W., Vis A.N., Roobol M.J., et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 174 (2005) 121-125
54. Cooperberg M.R., Lubeck D.P., Mehta S.S., and Carroll P.R. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170 (2003) S21-S25 discussion S26-7
55. Horninger W., Berger A., Pelzer A., et al. Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol 12 (2005) 7-13 discussion 92-3
56. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
57. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
58. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
59. Holmberg L., Bill-Axelson A., Helgesen F., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 (2002) 781-789
60. Studer U.E., Hauri D., Hanselmann S., et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 22 (2004) 4109-4118
61. Klotz L. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Clin Pract Urol 2 (2005) 136-142 quiz 1 p following 149
62. Hewitson P., and Austoker J. Part 2: Patient information, informed decision-making and the psycho-social impact of prostate-specific antigen testing. BJU Int 95 (2005) 16-32
63. Sennfalt K., Sandblom G., Carlsson P., and Varenhorst E. Costs and effects of prostate cancer screening in Sweden-a 15-year follow-up of a randomized trial. Scand J Urol Nephrol 38 (2004) 291-298
64. Murphy A.M., McKiernan J.M., and Olsson C.A. Controversies in prostate cancer screening. J Urol 172 (2004) 1822-1824
65. Patel S.H. Serum prostate-specific antigen screening for prostate cancer: application of current evidence to model criteria. Appl Health Econ Health Policy 2 (2003) 79-83